Q3 FY2026 · ended Sep 30, 2026 · Revenue $0, -100.0% YoY · Filed Oct 27, 2026
Rallybio Corporation (RLYB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $0 and a net loss of $2.7 million. As of Sep 30, 2026 it held $90.7 million in cash and investments and $0 in total debt.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-2.73M
-117.0% vs year-ago quarter
Operating cash flow
$-2.28M
+65.3% vs year-ago quarter
Free cash flow
—
EPS
$-0.48
-116.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
5.38M
-87.3% vs year-ago quarter
Net cash
$90.69M
Q3 FY2026
Operating margin
-5580.9%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RLYB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1739410
- Former names
- Rallybio Holdings, LLC (until Jun 7, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $212,000 | $222,000 | $212,000 |
| Operating income | -$3.4M | -$5.7M | -$8.7M | -$6.4M | -$6.9M |
| Net income | -$2.7M | $43.7M | -$8.3M | -$5.9M | $16.0M |
| Diluted EPS | -$0.48 | $7.53 | -$1.46 | -$1.03 | $2.84 |
| Operating cash flow | -$2.3M | $45.9M | -$8.0M | -$4.7M | -$6.5M |
| Total assets | $95.6M | $98.1M | $54.5M | $62.3M | $67.7M |
| Total liabilities | $3.3M | $3.6M | $4.2M | $4.3M | $4.6M |
| Stockholders' equity | $92.3M | $94.5M | $50.3M | $58.0M | $63.0M |
| Cash and investments | $90.7M | $92.8M | $46.8M | $54.7M | $59.3M |
| Total debt | $0 | $0 | $154,000 | $176,000 | $198,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Shareholder vote results, Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Oct 27, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 25, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 9, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change in control, Officer or director change, Regulation FD disclosure
|
Jun 1, 2026 | May 31, 2026 |
All 308 Rallybio Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.